Search by Drug Name or NDC
NDC 00173-0521-00 SEREVENT 50 ug/1 Details
SEREVENT 50 ug/1
SEREVENT is a ORAL; RESPIRATORY (INHALATION) POWDER, METERED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by GlaxoSmithKline LLC. The primary component is SALMETEROL XINAFOATE.
MedlinePlus Drug Summary
Salmeterol is used to control wheezing, shortness of breath, coughing, and chest tightness in people with chronic obstructive pulmonary disease (COPD; a group of lung diseases that includes chronic bronchitis and emphysema). It is also used along with an inhaled steroid medication to control wheezing, shortness of breath, coughing, and chest tightness and in adults and children 4 years of age and older with asthma. It is also is used to prevent bronchospasm (breathing difficulties) during exercise in adults and children 4 years of age and older. Salmeterol is in a class of medications called long-acting beta agonists (LABAs). It works by relaxing and opening air passages in the lungs, making it easier to breathe.
Related Packages: 00173-0521-00Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Salmeterol Oral Inhalation
Product Information
| NDC | 00173-0521 |
|---|---|
| Product ID | 0173-0521_a2d4003d-3b54-492d-a9d2-5236358bdf05 |
| Associated GPIs | 44201058108020 |
| GCN Sequence Number | 031417 |
| GCN Sequence Number Description | salmeterol xinafoate BLST W/DEV 50 MCG INHALATION |
| HIC3 | B6Y |
| HIC3 Description | BETA-ADRENERGIC AGENTS, ORALLY INHALED,LONG ACTING |
| GCN | 64012 |
| HICL Sequence Number | 007393 |
| HICL Sequence Number Description | SALMETEROL XINAFOATE |
| Brand/Generic | Brand |
| Proprietary Name | SEREVENT |
| Proprietary Name Suffix | DISKUS |
| Non-Proprietary Name | salmeterol xinafoate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | POWDER, METERED |
| Route | ORAL; RESPIRATORY (INHALATION) |
| Active Ingredient Strength | 50 |
| Active Ingredient Units | ug/1 |
| Substance Name | SALMETEROL XINAFOATE |
| Labeler Name | GlaxoSmithKline LLC |
| Pharmaceutical Class | Adrenergic beta2-Agonists [MoA], beta2-Adrenergic Agonist [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA020692 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00173-0521-00 (00173052100)
| NDC Package Code | 0173-0521-00 |
|---|---|
| Billing NDC | 00173052100 |
| Package | 1 INHALER in 1 CARTON (0173-0521-00) / 60 POWDER, METERED in 1 INHALER |
| Marketing Start Date | 1997-11-25 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 6.76115 |
| Pricing Unit | EA |
| Effective Date | 2023-03-22 |
| NDC Description | SEREVENT DISKUS 50 MCG |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 2, 5 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |